THIS WEBSITE IS INTENDED FOR US HEALTHCARE PROFESSIONALS ONLY.

  • Explore by Tumor Type
  • Molecular Pathways
    • Pathways Overview
    • Cancer Immunity Targets
      • CD20 CD3
      • CEA CD3
      • PD-L1
    • Tumor Targets
      • ALK
      • B Cells
      • BCL-2
      • CD79b
      • HER Pathways
      • MAPK
      • MDM2
      • PI3K/AKT
      • ROS1
      • TRK
      • VEGF
  • Development Platforms
    • Platforms Overview
    • Antibody Drug Conjugates
    • Monoclonal Antibodies
    • Personalized Cancer Vaccines
    • Small Molecules
    • T-cell Bispecific Antibodies
  • Investigational Therapies
    • Pipeline Overview
    • Clinical Development Approach
  • Clinical Trials
    • Currently Enrolling Trials
    • Clinical Trial Phases and Design
    • Clinical Endpoints: Efficacy
    • Clinical Endpoints: Safety
  • Explore by Tumor Type
  1. Home

Discover CD79b in B-cell malignancies

Learn More

See why PD-L1 is fundamental to dual pathway targeting strategies

Learn More

Disease pathways and cancer immunity targets

Discover the cancer immunity cycle and immune phenotypes

Delve into the science of harnessing the potential immune response in patients with cancer.

Explore Cancer Immunity Targets

Disease pathways and tumor targets

Read more about targeted strategies

Learn more about ongoing research in identifying and validating tumor targets and pathways.

Explore Tumor Targets

  • Explore ALK malignanciesALK
  • Explore B-cell malignanciesB CELLS
  • Explore CD79b malignanciesCD79b
  • Explore oncogenic HER signalingHER PATHWAYS
  • ROS1
  • TRK

Explore all Molecular Pathways

Customize your search

Search BioOncology.com based on the types of tumors, phases of clinical development, or scientific platforms that interest you.

EXPLORE BY TUMOR TYPE

Register for updates

Stay connected to oncology research, news, and developments from Genentech BioOncology.

Register now

2019
  • Contact Us
  • Privacy Policy
  • Terms & Conditions
  • Site Map

© [YEAR] Genentech USA, Inc. All rights reserved.

Link to Third Party Site

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Cancel OK

Link to Healthcare Professionals Site

The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.

Cancel OK

Cancel

Your email has been sent!

Thanks for sharing this page.